Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/1/15  and contains information from public web pages and contributions from the ZoomInfo community.

President and Co-Founder

Phone: (319) ***-****  HQ Phone
Cellular Engineering Technologies Inc.
2660 Crosspark Road Suite 135
Coralville , Iowa 52241
United States

Company Description: Cellular Engineering Technologies (CET) is an emerging biotechnology company in tissue engineering focused on developing novel technologies to expedite the drug...   more

Employment History

Board Memberships and Affiliations


  • degree , biochemistry
    University of California at Davis
55 Total References
Web References
The John Paul II Stem Cell Research Institute - Board Members, 21 Feb 2012 [cached]
Alan Moy MD. Scientific Director of John Paul II Stem Cell Research Institute, CEO, Cellular Engineering Technologies, Inc, Adjunct Associate Professor, College of Engineering, University of Iowa
The John Paul II Medical Research ..., 27 Aug 2014 [cached]
The John Paul II Medical Research Institute, founded in 2008 by Dr. Alan Moy, an Iowa City pulmonologist, has gotten “hundreds of thousands” of dollars in donations from people who want to support research on Amyotrophic Lateral Sclerosis (ALS), but don't want the research done with human embryos, said CEO Jay Kamath.
Moy, the scientific director, collects tissue samples from patients who want to participate in research. | Local News, 7 Jan 2006 [cached]
CET, founded in 2000 by its president and chief executive officer, Dr. Alan Moy, operated through the University of Iowa until July 2005.
"The question is what is the ..., 16 Jan 2011 [cached]
"The question is what is the benefit of using embryonic stem cells as treatments," said Alan Moy, a scientist who started Coralville's John Paul II Stem Cell Research Institute, a nonprofit group opposed to the use of embryonic stem cell research.
The group, the largest anti-abortion organization in the state, directed questions to Moy, the scientist who started the John Paul II Research Institute, as well as Kim Lehman, its past president.
Moy finds fault with the argument that the eggs would be destroyed anyway. Some countries prevent fertilization clinics from creating excess embryos, which he believes is a more ethical approach.
"The only reason why those embryos are being discarded is because nobody wants to pay for the freezing costs to maintain those," Moy said.
Alan Moy believes that embryonic stem cells are not necessary to advance regenerative medical research.
The former University of Iowa scientist has a lot riding on that belief: In 2000, he launched his own business that specializes in stem cell research without using embryonic cells.
He also heads a nonprofit group whose mission is to advance stem cell research "in a manner consistent with pro-life bioethics."
"I look at it from different levels, one of which is an ethical issue," Moy said. I'm pro-life. But I also look at it from a strategic perspective. … It's very concerning that government is not looking at this from a global competitive economy perspective."
Moy believes governments have blindly poured resources into embryonic stem cell research. Money would be better spent on pumping up the private sector's regenerative medicine industry that uses cells derived by alternative methods to the destruction of a human embryo, he said.
Moy employs six people at his Coralville business, Cellular Engineering Technologies. Part of his work is to mass produce what is known as induced pluripotent stem cells, which are sold to researchers.
The pluripotent cells are derived from areas such as the skin of human volunteers and are reprogrammed to assume an embryonic stem cell-like state by forcing the expression of certain genes.
Scientists are still conducting research to determine whether the pluripotent cells differ significantly from embryonic stem cells.
In the meantime, Moy's business continues to develop what he says will soon be the nation's largest repository of disease-specific pluripotent cells to help other researches conquer or treat cancers, autism, Alzheimer's and other diseases.
Think of his business as a pluripotent megastore.
"It's a very exciting time, and it is working on things that potentially have cures for patients while also providing economic development for the state," Moy said.
CET - About CET, 18 Jan 2015 [cached]
Alan Moy, MD Chief Executive Officer and Founder
Alan Moy, M.D., a physician-scientist, was previously on faculty for 13 years at the University of Iowa Department of Internal Medicine and Biomedical Engineering. Dr. Moy founded the company in 2000. Dr. Moy received a Bachelor's degree in Biochemistry from the University of California, Davis and an M.D. from Creighton University. He received postgraduate education in Internal Medicine from St. Louis University and completed a fellowship in Pulmonary Medicine and Critical Care Medicine at the University of Iowa. Dr. Moy's research expertise is in the area of vascular biology and tissue engineering. Dr. Moy is also listed in the 2010 Who's Who in America and is listed in 2011 as a Leading Physician of the World by the International Association of Healthcare Professions.
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.